- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00001074
The Safety and Effectiveness of Hydroxyurea and ddI Used Individually or Together in HIV-Infected Patients
A Phase I/II Dosing Study of the Safety and Antiretroviral Activity of Hydroxyurea Alone and in Combination With ddI Compared With ddI Alone in Subjects With HIV Infection
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Current antiviral therapies for HIV-1 are limited by a few choices, and the lack of sustained clinical benefit from the drugs. The mechanisms that account for the lack of prolonged inhibition of viral replication by these agents are not fully understood. The activity of RT inhibitors might be potentiated by inhibiting host cellular enzymes essential for efficient HIV reverse transcription. Based on this information, comparisons of the antiviral effects of ddI monotherapy and hydroxyurea plus ddI, with the cellular enzyme ribonucleotide reductase as a potential target, should be done.
This is a 24-week study, with two 12-week treatment periods. Patients are randomized to one of five treatment arms based upon a patient's history of antiretroviral therapy (naive vs. experienced). The five treatment arms are:
- ddI plus hydroxyurea placebo.
- hydroxyurea (lower dose) plus ddI placebo for 4 weeks; then hydroxyurea (higher dose) plus ddI.
- hydroxyurea (higher dose) plus ddI placebo for 4 weeks; then hydroxyurea (higher dose) plus ddI.
- hydroxyurea (lower dose) plus ddI.
- hydroxyurea (higher dose) plus ddI. After the completion of week 12, patients on combination therapy remain on their current therapy and patients on ddI plus placebo have hydroxyurea replace the placebo at 1 of 2 assigned doses (1:1 randomization). AS PER AMENDMENT 5/5/97: If after the 24-week treatment period, a patient has an RNA level less than or equal to 5,000 copies/ml or less than 20,000 copies/ml with a greater than 1 log10 decline from baseline, she has the option to continue therapy open-label ddI plus hydroxyurea for an additional 24 weeks.
AS PER AMENDMENT 10/1/97: Accrual to the arms involving hydroxyurea alone has been closed. Patients are randomized to one of the three treatment arms, as follows:
- hydroxyurea placebo plus ddI.
- hydroxyurea (lower dose) plus ddI.
- hydroxyurea (higher dose) plus ddI.
Studientyp
Einschreibung
Phase
- Phase 1
Kontakte und Standorte
Studienorte
-
-
California
-
San Diego, California, Vereinigte Staaten, 921036325
- Univ of California / San Diego Treatment Ctr
-
San Francisco, California, Vereinigte Staaten, 94115
- Stanford at Kaiser / Kaiser Permanente Med Ctr
-
Stanford, California, Vereinigte Staaten, 943055107
- Stanford Univ Med Ctr
-
Torrance, California, Vereinigte Staaten, 90502
- Harbor UCLA Med Ctr
-
-
Colorado
-
Denver, Colorado, Vereinigte Staaten, 80262
- Univ of Colorado Health Sciences Ctr
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21287
- Johns Hopkins Hosp
-
-
New York
-
New York, New York, Vereinigte Staaten, 10003
- Beth Israel Med Ctr
-
New York, New York, Vereinigte Staaten, 10016
- Bellevue Hosp / New York Univ Med Ctr
-
New York, New York, Vereinigte Staaten, 10029
- Mount Sinai Med Ctr
-
-
North Carolina
-
Chapel Hill, North Carolina, Vereinigte Staaten, 275997215
- Univ of North Carolina
-
Durham, North Carolina, Vereinigte Staaten, 27710
- Duke Univ Med Ctr
-
-
Ohio
-
Cincinnati, Ohio, Vereinigte Staaten, 452670405
- Univ of Cincinnati
-
Cleveland, Ohio, Vereinigte Staaten, 44106
- Case Western Reserve Univ
-
Cleveland, Ohio, Vereinigte Staaten, 441091998
- MetroHealth Med Ctr
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19104
- Univ of Pennsylvania at Philadelphia
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 191075098
- Thomas Jefferson Univ Hosp
-
-
South Carolina
-
West Columbia, South Carolina, Vereinigte Staaten, 29169
- Julio Arroyo
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten, 981224304
- Univ of Washington
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria
Concurrent Medication:
Allowed:
AS PER AMENDMENT 5/5/97:
- PCP prophylaxis with trimethoprim/sulfamethoxazole or Dapsone.
Patients must have:
- HIV-1 infection.
- AS PER AMENDMENT 5/5/97:
- CD4 count of 200 - 700 cells/mm3 within 60 days prior to study entry.
- AS PER AMENDMENT 10/1/97:
- HIV RNA plasma level < 20,000 copies/ml within 60 days of enrollment (obtained at a laboratory certified to perform the Roche Monitor assay).
Exclusion Criteria
Co-existing Condition:
Patients with any of the following symptoms or conditions are excluded:
- CMV, MAC, toxoplasmosis, or disseminated fungal infection requiring acute or chronic therapy.
- Significant medical illness as determined by investigator.
- Active diagnosis of any malignancy, including visceral Kaposi's sarcoma or extensive cutaneous Kaposi's sarcoma for which systemic chemotherapy is anticipated within the next 24 weeks.
- Current Grade 2 or greater peripheral neuropathy.
Concurrent Medication:
Excluded:
- Acute or chronic therapy for CMV, MAC, toxoplasmosis, or disseminated fungal infection.
AS PER AMENDMENT 5/5/97:
- All antiretroviral medications other than those provided on study.
- Systemic chemotherapy for active malignancies, including systemic treatment for KS.
- Agents with myelosuppressive potential, including tegretol, carboplatin, carmustine, cyclophosphamide and fluorouracil.
- Granulocyte colony stimulating factor (G-CSF) except while hydroxyurea or matching placebo is held.
Drugs associated with peripheral neuropathy, including:
- hydralazine, disulfiram, nitrofurantoin, cisplatinum, diethyldithiocarbamate, gold, rifampin, chloramphenicol, clioquinol, ethambutol, ethionamide, glutethimide, sodium cyanate, and thalidomide.
Patients with any of the prior conditions are excluded:
- History of transfusion dependent anemia, defined as any history of repeated transfusion with two or more units of red blood cells.
- At the discretion of the investigator, history of pancreatitis.
Prior Medication:
Excluded:
- More than 2 weeks prior treatment with ddI.
AS PER AMENDMENT 5/5/97:
- Other antiretrovirals must be discontinued at least 14 days prior to randomization.
- Prior hydroxyurea.
- Any candidate HIV vaccine or agent with potential immune modulating effects within the past 30 days.
- Any colony stimulating factor or erythropoietin within the past 60 days.
Prior Treatment:
Excluded:
- Transfusion with red blood cells within the past 60 days.
Risk Behavior:
Excluded:
- At the investigator's discretion, any active substance abuse, including alcohol abuse interfering with compliance.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
Mitarbeiter und Ermittler
Ermittler
- Studienstuhl: Ian Frank, MD, Division of Infectious Diseases, University of Pennsylvania
- Studienstuhl: Joseph Eron, MD, University of North Carolina
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Frank I, Boucher H, Fiscus S, Flexner C, Valentine F, Gulick R, Fox L, Eron J. Phase I/II dosing study of once-daily hydroxyurea (HU) alone vs didanosine (ddI) alone vs ddI + HU. Conf Retroviruses Opportunistic Infect. 1999 Jan 31-Feb 4;6th:143 (abstract no 402)
- Frank I, Bosch RJ, Fiscus S, Valentine F, Flexner C, Segal Y, Ruan P, Gulick R, Wood K, Estep S, Fox L, Nevin T, Stevens M, Eron JJ Jr; ACTG 307 Protocol Team. Activity, safety, and immunological effects of hydroxyurea added to didanosine in antiretroviral-naive and experienced HIV type 1-infected subjects: a randomized, placebo-controlled trial, ACTG 307. AIDS Res Hum Retroviruses. 2004 Sep;20(9):916-26. doi: 10.1089/aid.2004.20.916.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- RNA-Virusinfektionen
- Viruserkrankungen
- Durch Blut übertragene Infektionen
- Übertragbare Krankheiten
- Sexuell übertragbare Krankheiten, viral
- Sexuell übertragbare Krankheiten
- Lentivirus-Infektionen
- Retroviridae-Infektionen
- Immunologische Mangelsyndrome
- Erkrankungen des Immunsystems
- Langsame Viruserkrankungen
- HIV-Infektionen
- Infektionen
- Erworbenes Immunschwächesyndrom
- Molekulare Mechanismen der pharmakologischen Wirkung
- Antiinfektiva
- Antivirale Mittel
- Reverse-Transkriptase-Inhibitoren
- Inhibitoren der Nukleinsäuresynthese
- Enzym-Inhibitoren
- Anti-HIV-Agenten
- Antiretrovirale Mittel
- Antimetaboliten
- Antineoplastische Mittel
- Antisickling-Mittel
- Hydroxyharnstoff
- Didanosin
Andere Studien-ID-Nummern
- ACTG 307
- 11282 (Registrierungskennung: DAIDS ES)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur HIV-Infektionen
-
Duke UniversityAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)Vereinigte Staaten
-
Catholic University of the Sacred HeartAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)
-
Abbott Medical DevicesThoratec CorporationAbgeschlossenDriveline Heart-assisted Device Related InfectionVereinigte Staaten
-
Princess Maxima Center for Pediatric OncologyUMC Utrecht; Dutch Cancer SocietyRekrutierungCentral Line-associated Bloodstream Infection (CLABSI)Niederlande
-
University of MalayaTeleflexRekrutierungCLABSI – Central Line Associated Bloodstream InfectionMalaysia
-
National Taiwan University Hospital Hsin-Chu BranchAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)
-
Johns Hopkins UniversityAbgeschlossenCLABSI – Central Line Associated Bloodstream InfectionVereinigte Staaten
-
National Taiwan University HospitalAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)Taiwan
-
University of ZurichNoch keine RekrutierungCentral Line-associated Bloodstream Infection (CLABSI) | Katheterbedingte Blutstrominfektion
-
Princess Anna Mazowiecka Hospital, Warsaw, PolandNutricia FoundationAktiv, nicht rekrutierendWachstumsfehler | CLABSI – Central Line Associated Bloodstream InfectionPolen
Klinische Studien zur Didanosin
-
Institut de Recherche pour le DeveloppementAbgeschlossen
-
Mansoura University Children HospitalAbgeschlossen
-
Tuberculosis Research Centre, IndiaIndian Council of Medical Research; National AIDS Control OrganisationUnbekanntTuberkulose | Infektionen mit dem Human Immunodeficiency VirusIndien
-
University of ParmaUniversity of Birmingham; Azienda Ospedaliero-Universitaria di Parma; Centro de...AbgeschlossenKardiometabolische Gesundheit | Individuelle Variabilität im (Poly)PhenolstoffwechselItalien
-
National Institute of Allergy and Infectious Diseases...Bristol-Myers SquibbAbgeschlossenHIV-InfektionenVereinigte Staaten, Puerto Rico
-
Bristol-Myers SquibbAbgeschlossen
-
Bristol-Myers SquibbAbgeschlossenHIV-InfektionenVereinigte Staaten
-
Assistance Publique - Hôpitaux de ParisSuspendiertHIV-InfektionenFrankreich
-
National Institute of Allergy and Infectious Diseases...Bristol-Myers SquibbAbgeschlossen
-
National Institute of Allergy and Infectious Diseases...Abgeschlossen